Identification of Acyl-Protein Thioesterase-1 as a Polysorbate-degrading Host Cell Protein in a Monoclonal Antibody Formulation Using Activity-based Protein Profiling.

Antibody drug(s) Enzyme(s) Hydrolysis Liquid Chromatography-Mass Spectrometry (LC-MS) Monoclonal antibody(s) Protein formulation(s) Surfactant(s)

Journal

Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R

Informations de publication

Date de publication:
19 May 2024
Historique:
received: 18 03 2024
revised: 13 05 2024
accepted: 13 05 2024
medline: 22 5 2024
pubmed: 22 5 2024
entrez: 21 5 2024
Statut: aheadofprint

Résumé

Polysorbate (PS) degradation in monoclonal antibody (mAb) formulations poses a significant challenge in the biopharmaceutical industry. PS maintains protein stability during drug product's shelf life but is vulnerable to breakdown by low-abundance residual host cell proteins (HCPs), particularly hydrolytic enzymes such as lipases and esterases. In this study, we used activity-based protein profiling (ABPP) coupled with mass spectrometry to identify acyl-protein thioesterase-1 (APT-1) as a polysorbate-degrading HCP in one case of mAb formulation with stability problems. We validated the role of APT1 by matching the polysorbate degradation fingerprint in the mAb formulation with that of a recombinant APT1 protein. Furthermore, we found an agreement between APT1 levels and PS degradation rates in the mAb formulation, and we successfully halted PS degradation using APT1-specific inhibitors ML348 and ML211. APT1 was found to co-purify with a specific mAb via hitchhiking mechanism. Our work provides a streamlined approach to identifying critical HCPs in PS degradation, supporting quality-by-design principles in pharmaceutical development.

Identifiants

pubmed: 38772451
pii: S0022-3549(24)00185-0
doi: 10.1016/j.xphs.2024.05.013
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Ernest Šprager (E)

University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia; Novartis Technical Research & Development, Biologics Technical Development Mengeš, Novartis Pharmaceutical Manufacturing LLC, Slovenia.

Jens Möller (J)

Novartis Technical Research & Development, Analytical Characterization, Novartis Pharmaceutical Manufacturing GmbH, Kundl, Austria.

Yuhsien Lin (Y)

Novartis Technical Research & Development, Analytical Characterization, Novartis Pharmaceutical Manufacturing GmbH, Kundl, Austria.

Veronika Reisinger (V)

Novartis Technical Research & Development, Analytical Characterization, Novartis Pharmaceutical Manufacturing GmbH, Kundl, Austria.

Tomaž Bratkovič (T)

University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia.

Mojca Lunder (M)

University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia.

Jožica Vašl (J)

Novartis Technical Research & Development, Biologics Technical Development Mengeš, Novartis Pharmaceutical Manufacturing LLC, Slovenia.

Aleksander Krajnc (A)

Novartis Technical Research & Development, Biologics Technical Development Mengeš, Novartis Pharmaceutical Manufacturing LLC, Slovenia. Electronic address: aleksander.krajnc@novartis.com.

Classifications MeSH